Nippon Life Global Investors Americas Inc. Buys 20,060 Shares of CVS Health Corporation $CVS

Posted by Stanley Muller on Nov 2nd, 2026

Nippon Life Global Investors Americas Inc. lifted its stake in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 5.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 367,540 shares of the pharmacy operator’s stock after buying an additional 20,060 shares during the period. CVS Health makes up about 1.3% of Nippon Life Global Investors Americas Inc.’s portfolio, making the stock its 26th largest position. Nippon Life Global Investors Americas Inc.’s holdings in CVS Health were worth $31,495,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in CVS Health in the 2nd quarter valued at $12,747,462,000. State Street Corp boosted its holdings in CVS Health by 26.3% during the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock worth $7,751,205,000 after acquiring an additional 15,604,883 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock worth $3,496,725,000 after acquiring an additional 11,233,381 shares in the last quarter. Bank of America Corp DE grew its stake in shares of CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock worth $2,398,868,000 after acquiring an additional 13,836,701 shares in the last quarter. Finally, Pzena Investment Management LLC purchased a new stake in shares of CVS Health in the second quarter valued at about $1,217,558,000. Institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: One valuation analysis says CVS could be approximately 27% undervalued, with the next earnings report providing a potential catalyst. Analysts reportedly expect quarterly earnings of about $1.62 per share, making segment performance and management commentary important for the shares. CVS Health Could Be 27% Undervalued As Earnings Focus Sharpens
Positive Sentiment: CVS’s free Project Health screenings, which do not require appointments or insurance, support the company’s community-health strategy and could strengthen patient engagement and brand visibility. The immediate financial impact is likely limited. CVS Health Project Health Screenings
Neutral Sentiment: Articles highlight CVS’s broader strategy of combining healthcare services with housing and other social-support initiatives. The approach may improve long-term outcomes and customer retention, but near-term earnings effects are unclear. CVS Health Beyond Housing
Neutral Sentiment: Analyst-estimate and ratings coverage provides context ahead of earnings but does not identify a clear change in consensus or a new company-specific catalyst. CVS Health Stock Analyst Estimates and Ratings
Negative Sentiment: The University of Kentucky and five other hospital systems are suing CVS over alleged fraud or prescription-contract breaches. The claims, including a reported $41 million UK lawsuit, create litigation, reimbursement, and reputational risks, although the allegations have not been proven. Hospital Systems Sue CVS UK Sues CVS Health
Negative Sentiment: CVS reportedly faces as much as $2 billion of Medicare ratings-related risk. Any reduction in Medicare Advantage star ratings could hurt bonus payments, membership economics, and expectations for future earnings. CVS Health Medicare Ratings Risk

CVS Health Stock Performance

Shares of CVS stock opened at $90.20 on Monday. The firm’s 50 day moving average is $91.22 and its 200 day moving average is $88.76. The stock has a market capitalization of $115.36 billion, a P/E ratio of 23.86, a PEG ratio of 0.84 and a beta of 0.58. CVS Health Corporation has a 12 month low of $69.51 and a 12 month high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same period in the previous year, the business earned $1.81 EPS. CVS Health’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be paid a dividend of $0.6650 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Thursday, October 22nd. CVS Health’s payout ratio is presently 70.37%.

Wall Street Analysts Forecast Growth

CVS has been the topic of several analyst reports. Wells Fargo & Company boosted their price target on shares of CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Barclays upped their target price on CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. HSBC reaffirmed a “hold” rating and set a $103.00 price target on shares of CVS Health in a research report on Monday, July 6th. Robert W. Baird set a $107.00 price target on CVS Health in a report on Thursday, August 6th. Finally, Wall Street Zen cut CVS Health from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 19th. Nineteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $109.64.

Read Our Latest Stock Report on CVS

About CVS Health

(Free Report)

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.